{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:51:59Z","timestamp":1772117519945,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd002922.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000}}],"reference-count":305,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002922.pub3","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T18:49:33Z","timestamp":1354819773000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment for lupus nephritis"],"prefix":"10.1002","author":[{"given":"Lorna","family":"Henderson","sequence":"first","affiliation":[{"name":"The University of Sydney at Westmead; Centre for Transplant and Renal Research, Westmead Millennium Institute; Westmead NSW Australia 2145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Masson","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S","family":"Flanc","sequence":"additional","affiliation":[{"name":"Monash Medical Centre; Department of Nephrology; Clayton Rd Clayton VIC Australia 3168"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A","family":"Roberts","sequence":"additional","affiliation":[{"name":"Austin Health; Department of Nephrology; PO Box 5555 Heidelberg VIC Australia 3084"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy 70100"},{"name":"Mario Negri Sud Consortium; Department of Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy"},{"name":"Diaverum; Medical-Scientific Office; Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela C","family":"Webster","sequence":"additional","affiliation":[{"name":"The University of Sydney at Westmead; Centre for Transplant and Renal Research, Westmead Millennium Institute; Westmead NSW Australia 2145"},{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"key":"10.1002\/14651858.CD002922.pub3-BIB0001|cit1","unstructured":"Abd-ELHady El-Sehemy M Al-Saaran AM Al-Saeed Baddour NM El-Sayed Moez P Adam AG Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal) 2004 48"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0002|cit2","unstructured":"Abd-ELHady El-Sehemy M Al-Saaran AM Al-Saeed Baddour NM El-Sayed Moez P Gaber Adam A Cyclosporine but not cyclophosphamide is a rescue therapy in resistant lupus nephritis even in class iv proliferative GN [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal) 2004 48"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0003|cit3","first-page":"122A","article-title":"Prospective comparative study between azathioprine \"AZA\", cyclophosphamide \"CYP\", cyclosporine \"CsA\" and mycophenolate mofetil \"MMF\" in the treatment of lupus nephritis: is CYP still the preferred therapy against the new -comer MMF. AZA: an old drug with still a great potential? [abstract]","volume":"15","author":"Adam","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0004|cit4","first-page":"39","article-title":"Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis","volume":"13","author":"Sehemy","year":"2006","journal-title":"Egyptian Journal of Immunology\/Egyptian Association of Immunologists"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub3-BIB0006|cit6","first-page":"47A","article-title":"Mycophenolate mofetil compared with intravenous cyclophosphamide as induction therapy for lupus nephritis: Aspreva Lupus Management Study (ALMS) results [abstract]","volume":"18","author":"Appel","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0007|cit7","unstructured":"Clancy RM Association of adiponectin and soluble endothelial protein C receptor (sEPCR) with longitudinal assessments in the induction phase of a randomized multicenter trial comparing mycophenolate mofetil and intravenous cyclophosphamide [abstract] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/acr.20397","article-title":"Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide","volume":"63","author":"Dall'Era","year":"2011","journal-title":"Arthritis care & research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0009|cit9","first-page":"125","article-title":"Aspreva lupus management study (ALMS): maintenance results analysis by racial subgroup [abstract]","volume":"70","author":"Dooley","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"20","key":"10.1002\/14651858.CD002922.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0011|cit11","unstructured":"Ginzler E Contribution of vascular well being to the therapeutic response in the induction phase of a randomized multicenter trial comparing MMF to IVC [abstract] ACR\/ARHP Annual Scientific Meeting; 2008 Oct 24-29; San Francisco (CA) 2008"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0012|cit12","unstructured":"Ginzler EM Appel GB Dooley MA Isenberg D Jayne D Solomons N Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): efficacy by racial group [abstract] ACR\/ARHP Annual Scientific Meeting; 2007 Nov 6-11; Boston (MA) 2007"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.25052","article-title":"Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial","volume":"62","author":"Ginzler","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0017|cit14","first-page":"23","article-title":"Lessons from the Aspreva Lupus Management Study [abstract]","volume":"68","author":"Isenberg","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0014|cit15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology"},{"issue":"Supp II","key":"10.1002\/14651858.CD002922.pub3-BIB0015|cit16","first-page":"53","article-title":"Mycophenolate mofetil compared with intravenous cyclophosphamide as induction for lupus nephritis: ALMS results and BILAG responses [abstract]","volume":"67","author":"Isenberg","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub3-BIB0016|cit17","first-page":"606","article-title":"Mycophenolate mofetil (MMF, Cellcept) for induction and maintenance treatment of lupus nephritis (LN): baseline demographics of patients from the phase III randomized, controlled ASPREVA Lupus Management Study (ALMS) [abstract]","volume":"66","author":"Isenberg","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0018|cit18","first-page":"25A","article-title":"Results of the Aspreva Lupus Management Study (ALMS) maintenance phase [abstract]","volume":"21","author":"Jayne","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0019|cit19","unstructured":"Nadig RS Efficacy, toxicity and tolerability of mycophenolate mofetil in patients with lupus nephritis, based on dose\/weight ratio [abstract] ACR\/ARHP Annual Scientific Meeting; 2007 Nov 6-11; Boston (MA) 2007"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0020|cit20","unstructured":"Silva-Fernandez L Nadig RS von Gizycki H Ginzler EM Efficacy, toxicity and tolerability of mycophenolate mofetil in patients with lupus nephritis, based on dose\/weight ratio [abstract] ACR\/ARHP Annual Scientific Meeting; 2007 Nov 6-11; Boston (MA) 2007"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1177\/0961203307084712","article-title":"Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)","volume":"16","author":"Sinclair","year":"2007","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0022|cit22","first-page":"528A","article-title":"Protocol for the Aspreva Lupus Management Study (ALMS) [abstract]","volume":"16","author":"Sinclair","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Stone DH Dall'Era M Levesque V Cisternas MG Wofsy D Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil (MMF) or pulse cyclophosphamide (IV) [abstract] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009","DOI":"10.1002\/acr.20397"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0024|cit24","first-page":"27","article-title":"Aspreva lupus management study maintenance results [abstract]","volume":"19","author":"Wofsy","year":"2010","journal-title":"Lupus"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub3-BIB0025|cit25","first-page":"493","article-title":"Mycophenolate mofetil compared with intravenous cyclophosphamide in the treatment of lupus nephritis: predictors of response [abstract]","volume":"67","author":"Wofsy","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0026|cit26","first-page":"204","article-title":"Immunosuppressive therapy of lupus nephritis [abstract]","volume":"27","author":"Austin","year":"1985","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0002-9343(83)90338-8","article-title":"Prognostic factors in lupus nephritis. Contribution of renal histologic data","volume":"75","author":"Austin","year":"1983","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-99-1-1","article-title":"Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up","volume":"99","author":"Carette","year":"1983","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.7326\/0003-4819-83-5-606","article-title":"Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months","volume":"83","author":"Decker","year":"1975","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7326\/0003-4819-91-4-587","article-title":"NIH conference. Systemic lupus erythematosus: evolving concepts","volume":"91","author":"Decker","year":"1979","journal-title":"Annals of Internal Medicine"},{"issue":"6 (Pt 1)","key":"10.1002\/14651858.CD002922.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7326\/0003-4819-96-6-728","article-title":"Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis","volume":"96","author":"Dinant","year":"1982","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/art.1780340803","article-title":"Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only","volume":"34","author":"Steinberg","year":"1991","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000421703","article-title":"Cyclosporin plus steroids versus steroids alone in the treatment of lupus nephritis","volume":"99","author":"Balletta","year":"1992","journal-title":"Contributions to Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multi-target therapy","volume":"19","author":"Bao","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub3-BIB0036|cit36","first-page":"48a","article-title":"Successful treatment of class V+IV lupus nephritis with multi-target immunosuppressive therapy [abstract]","volume":"18","author":"Bao","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-3476(82)80203-5","article-title":"Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis","volume":"101","author":"Barron","year":"1982","journal-title":"Journal of Pediatrics"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/00045391-199512000-00005","article-title":"Misoprostol and prednisone treatment of lupus nephritis","volume":"2","author":"Belmont","year":"1995","journal-title":"American Journal of Therapeutics"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub3-BIB0039|cit39","first-page":"140A","article-title":"Comparative study of pulse treatment with cyclophosphamide or immunoglobulin to sustain the remission of lupus nephritis [abstract]","volume":"9","author":"Boletis","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9178","key":"10.1002\/14651858.CD002922.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(99)01575-5","article-title":"Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis","volume":"354","author":"Boletis","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0041|cit41","first-page":"411","article-title":"Prognostic indicators supporting use of short courses of pulse immunosuppression for severe lupus nephritis (LN) [abstract]","volume":"6","author":"Austin","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8822","key":"10.1002\/14651858.CD002922.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/art.10142","article-title":"Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies","volume":"46","author":"Illei","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000180176","article-title":"Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis","volume":"10","author":"Cade","year":"1973","journal-title":"Nephron"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub3-BIB0045|cit45","first-page":"195A","article-title":"Prolonged follow-up of patients with diffuse proliferative lupus nephritis (DPLN) treated with prednisolone and mycophenolate mofetil (MMF) [abstract]","volume":"12","author":"Chan","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub3-BIB0048|cit46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0961203308091285","article-title":"Mycophenolate mofetil in the treatment of lupus nephritis: 7 years on","volume":"17","author":"Chan","year":"2008","journal-title":"Lupus"},{"issue":"16","key":"10.1002\/14651858.CD002922.pub3-BIB0046|cit47","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0047|cit48","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1681\/ASN.2004080686","article-title":"Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis","volume":"16","author":"Chan","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM200102013440513","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis","volume":"344","author":"Karassa","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0050|cit50","unstructured":"Chen W Liu Q Chen W Fu P Liao Y Zhang J A prospective multicenter randomized trial of treatment of active lupus nephritis with tacrolimus versus cyclophosphamide\/azathioprine in Chinese adults [abstract SU248] World Congress of Nephrology; 2009 May 22-26; Milan (Italy) 2009"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","article-title":"Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial","volume":"57","author":"Chen","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0052|cit52","first-page":"171","article-title":"Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study","volume":"125","author":"Clark","year":"1981","journal-title":"CMAJ Canadian Medical Association Journal"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0053|cit53","first-page":"928","article-title":"Elective plasmapheresis in S.L.E. nephritis: pilot for a controlled prospective study [abstract]","volume":"16","author":"Clark","year":"1979","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0054|cit54","first-page":"353","article-title":"Long-term plasma exchange in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis","volume":"5","author":"Clark","year":"1984","journal-title":"Plasma Therapy & Transfusion Technology"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0055|cit55","first-page":"424","article-title":"Chronic plasma exchange in SLE nephritis [abstract]","volume":"24","author":"Clark","year":"1983","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0056|cit56","first-page":"629","article-title":"Chronic plasma exchange in systemic lupus erythematosus nephritis","volume":"20","author":"Clark","year":"1983","journal-title":"Proceedings of the European Dialysis & Transplant Association"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0057|cit57","first-page":"161","article-title":"A controlled trial of chronic plasma exchange therapy in S.L.E. nephritis [abstract]","volume":"25","author":"Clark","year":"1984","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0058|cit58","first-page":"147","article-title":"Controlled trial of chronic plasma exchange therapy in SLE nephritis [abstract]","volume":"21","author":"Clark","year":"1982","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0059|cit59","unstructured":"Linton AL Williams W Cattran D Lindsay R Clark W Controlled trial of chronic plasma exchange in SLE nephritis [abstract] Australasian Society of Nephrology.19th Annual Scientific Meeting. 2nd Asian Congress of Nephrology; 1983 Feb 14-18; Melbourne (Australia) 1983 48"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub3-BIB0060|cit60","first-page":"15A","article-title":"Maintenance therapy for proliferative forms of lupus nephritis: a randomized clinical trial comparing quarterly intravenous cyclophosphamide (IVCY) versus oral mycophenolate mofetil (MMF) or azathioprine (AZA) [abstract]","volume":"13","author":"Contreras","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub3-BIB0061|cit61","first-page":"38A","article-title":"Lupus nephritis: sequential therapy with short-term intravenous cyclophosphamide followed by maintenance oral mycophenolate mofetil or oral azathioprine is more efficacious and safer than long-term intravenous cyclophosphamide [abstract]","volume":"14","author":"Contreras","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub3-BIB0063|cit63","first-page":"99A","article-title":"Immunosupressive therapy for proliferative lupus nephritis: preliminary report of a prospective, randomized clinical trial with mycophenolate mofetil (MMF) [abstract]","volume":"10","author":"Contreras","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"s33","DOI":"10.1191\/0961203305LU2115OA","article-title":"Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide","volume":"14","author":"Contreras","year":"2005","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0065|cit65","unstructured":"Dostal C Tesar V Rysava R Rovensky J Rychlik I Hrneio Z Cyclofa-Lune (2002) lupus nephritis - randomized controlled multicentric therapeutic comparative study with cyclosporin A versus cyclophosphamide: running evaluation [abstract THU0390] Annual European Congress of Rheumatology EULAR 2004; 2004 Jun 9-12, Berlin (Germany) 2004"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study","volume":"19","author":"Zavada","year":"2010","journal-title":"Lupus"},{"issue":"3-4","key":"10.1002\/14651858.CD002922.pub3-BIB0067|cit67","first-page":"168","article-title":"Prospective multicentre trial on the short- term effects of plasma exchange versus cytotoxic drugs in corticosteroid-resistant lupus nephritis","volume":"33","author":"Derksen","year":"1988","journal-title":"Netherlands Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.1780170511","article-title":"Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine","volume":"17","author":"Donadio","year":"1974","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-77-6-829","article-title":"Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine","volume":"77","author":"Donadio","year":"1972","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0070|cit70","first-page":"465","article-title":"Long-term treatment of diffuse proliferative lupus nephritis (DPLN) with prednisone and combined prednisone and cyclophosphamide [abstract]","volume":"12","author":"Donadio","year":"1977","journal-title":"Kidney International"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub3-BIB0071|cit71","first-page":"484","article-title":"Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide","volume":"51","author":"Donadio","year":"1976","journal-title":"Mayo Clinic Proceedings"},{"issue":"21","key":"10.1002\/14651858.CD002922.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJM197811232992102","article-title":"Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide","volume":"299","author":"Donadio","year":"1978","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0073|cit73","first-page":"307","article-title":"Therapy of lupus nephritis. A two-year prospective study","volume":"145","author":"Doria","year":"1994","journal-title":"Annales de Medecine Interne"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0074|cit74","first-page":"A57","article-title":"Azathioprine and cyclophosphamide in treatment of patients with diffuse proliferative lupus nephritis - a randomized controlled study [abstract]","volume":"16","author":"Dyadyk","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub3-BIB0075|cit75","first-page":"467","article-title":"Azathioprine and cyclophosphamide in diffuse proliferative lupus nephritis treatment - a randomized controlled study [abstract]","volume":"66","author":"Dyadyk","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s10157-010-0270-7","article-title":"Is mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?","volume":"14","author":"Shafey","year":"2010","journal-title":"Clinical & Experimental Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/art.1780160204","article-title":"Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis","volume":"16","author":"Fries","year":"1973","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/rheumatology\/37.2.217","article-title":"Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria","volume":"37","author":"Fu","year":"1998","journal-title":"British Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2125.1997.00634.x","article-title":"Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis","volume":"44","author":"Fu","year":"1997","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/1529-0131(197607\/08)19:4<693::AID-ART1780190406>3.0.CO;2-2","article-title":"Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis","volume":"19","author":"Ginzler","year":"1976","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0081|cit81","first-page":"38A","article-title":"Multicenter controlled trial of mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN) [abstract]","volume":"14","author":"Appel","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ncpneph0184","article-title":"Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide","volume":"2","author":"Burchardi","year":"2006","journal-title":"Nature Clinical Practice Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ncprheum0217","article-title":"Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide","volume":"2","author":"Elliott","year":"2006","journal-title":"Nature Clinical Practice Rheumatology"},{"issue":"21","key":"10.1002\/14651858.CD002922.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc053503","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis","volume":"354","author":"Karassa","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0086|cit86","first-page":"8A","article-title":"Mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) for severe lupus nephritis (LN): subgroup analysis of patients with membranous nephropathy (SLE-V) [abstract]","volume":"16","author":"Radhakrishnan","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD002922.pub3-BIB0087|cit87","first-page":"779A","article-title":"Lupus membranous nephropathy IV cyclophosphamide (IVC) vs. mycophenolate mofetil (MMF) [abstract]","volume":"19","author":"Radhakrishnan","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0088|cit88","first-page":"55","article-title":"Should therapy go beyond the control of immediate injury? Biomarkers of the vasculature and their association with longitudinal assessments in the induction phase of a randomized multicenter trial comparing mycophenolate mofetil and intravenous cyclophosphamide [abstract]","volume":"19","author":"Robert","year":"2010","journal-title":"Lupus"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/art.10142","article-title":"Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies","volume":"46","author":"Illei","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0092|cit92","first-page":"350","article-title":"Cyclophosphamide versus azathioprine\/methylprednisolone: Long-term follow-up of the first Dutch lupus nephritis study [abstract]","volume":"20","author":"Arends","year":"2011","journal-title":"Lupus"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ndt\/gfm555","article-title":"Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis","volume":"23","author":"Grootscholten","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/art.22449","article-title":"Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis","volume":"56","author":"Grootscholten","year":"2007","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0095|cit95","unstructured":"Grootscholten C Bijl M Ligtenberg G Hagen EC van den Wall Bake AW de Glas-Vos JW Is azathioprine an alternative for cyclophosphamide in the treatment of patients with proliferative lupus nephritis? Two year results of the Dutch Lupus Nephritis Study [abstract OP0176] Annual European Congress of Rheumatology EULAR; 2004 Jun 9-12; Berlin (Germany) 2004"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/ard.2006.065425","article-title":"A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine\/methylprednisolone","volume":"66","author":"Grootscholten","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.ki.5001630","article-title":"Azathioprine\/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial","volume":"70","author":"Grootscholten","year":"2006","journal-title":"Kidney International"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0098|cit98","first-page":"54A","article-title":"Randomized controlled trial comparing cyclophosphamide pulse therapy with azathioprine\/methylprednisolone in proliferative lupus nephritis [abstract]","volume":"15","author":"Grootscholten","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub3-BIB0099|cit99","first-page":"1699","article-title":"Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine\/methylprednisolone in a randomized controlled trial","volume":"34","author":"Grootscholten","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub3-BIB0100|cit100","first-page":"14A","article-title":"Cyclophosphamide pulse therapy versus azathioprine and methylprednisolone pulses in proliferative lupus nephritis: first results of a randomized, prospective multicenter study [abstract]","volume":"13","author":"Ligtenberg","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"597","DOI":"10.7326\/0003-4819-83-5-597","article-title":"Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients","volume":"83","author":"Hahn","year":"1975","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD002922.pub3-BIB0102|cit102","first-page":"vi276","article-title":"A preliminary study of tacrolimus versus cyclophosphamide in patients with diffuse proliferative lupus nephritis [abstract]","volume":"22","author":"Hong","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0110|cit103","unstructured":"Houssiau FA The 10-year followup of the Euro-Lupus Nephritis Trial (ELNT), a randomized prospective trial comparing low-dose (LD) versus high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment of proliferative lupus nephritis [abstract 2060] ACR\/ARHP Annual Scientific Meeting; 2008 Oct 24-29; San Francisco (CL) 2008"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0103|cit104","unstructured":"Houssiau FA Cosyns J Cervera R The Euro-Lupus Nephritis Trial: 5-year follow-up [abstract OP0054] Annual European Congress of Rheumatology EULAR; 2003 June 18-21; Lisbon (Portugal) 2003"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub3-BIB0104|cit105","first-page":"64","article-title":"Long term outcome of patients randomized in the Euro-Lupus Nephritis Trial: further evidence that a low-dose IV cyclophosphamide induction regimen achieves good results [abstract]","volume":"65","author":"Houssiau","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub3-BIB0105|cit106","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub3-BIB0106|cit107","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/art.20666","article-title":"Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial","volume":"50","author":"Houssiau","year":"2004","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0107|cit108","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0108|cit109","unstructured":"Houssiau FA Vasconcelos C D'Cruz D Sebastiani GD de Ramon Garrido E Danieli MG Early response to immunosuppressive therapy predicts good long-term renal outcome in lupus nephritis: lessons from the Euro-Lupus Nephritis trial (ELNT) [abstract 67] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (USA) 2004"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0109|cit110","doi-asserted-by":"crossref","unstructured":"Houssiau FA Vasconcelos C D'Cruz D Sebastiani GD de Ramon Garrido E Danieli MG Early response to immunosuppressive therapy predicts good long-term renal outcome in proliferative lupus glomerulonephritis: lessons from the Euro-Lupus Nephritis Trial [abstract OP0174] Annual European Congress of Rheumatology EULAR; 2004 Jun 9-12; Berlin (Germany) 2004","DOI":"10.1002\/art.20666"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub3-BIB0112|cit111","first-page":"731A","article-title":"The value of a partial remission in severe lupus nephritis [abstract]","volume":"17","author":"Chen","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0111|cit112","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.03280807","article-title":"Value of a complete or partial remission in severe lupus nephritis","volume":"3","author":"Chen","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0113|cit113","first-page":"301","article-title":"Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"337","author":"Clough","year":"1990","journal-title":"Progress in Clinical & Biological Research"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","article-title":"Severe lupus nephritis: racial differences in presentation and outcome","volume":"18","author":"Korbet","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0197-2456(92)90030-4","article-title":"Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study","volume":"13","author":"Lachin","year":"1992","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-116-2-114","article-title":"Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide","volume":"116","author":"Levey","year":"1992","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0117|cit117","first-page":"208","article-title":"Primary outcomes in the controlled trial of plasmapheresis therapy (ppt) in severe lupus nephritis [abstract]","volume":"31","author":"Lewis","year":"1987","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0119|cit118","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jca.2920070314","article-title":"Plasmapheresis therapy is ineffective in SLE. Lupus Nephritis Collaborative Study Group","volume":"7","author":"Lewis","year":"1992","journal-title":"Journal of Clinical Apheresis"},{"issue":"21","key":"10.1002\/14651858.CD002922.pub3-BIB0118|cit119","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM199205213262101","article-title":"A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"326","author":"Lewis","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0961203310385267","article-title":"The prognosis of severe lupus nephritis based on the Modification of Diet in Renal Disease (MDRD) study estimated glomerular filtration rate","volume":"20","author":"Patel","year":"2011","journal-title":"Lupus"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0121|cit121","first-page":"230","article-title":"Plasmapheresis (PP) does not enhance the susceptibility to infections in immunosuppressed patients with lupus nephritis [abstract]","volume":"35","author":"Pohl","year":"1989","journal-title":"Kidney International"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"924","DOI":"10.7326\/0003-4819-114-11-924","article-title":"Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"114","author":"Pohl","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0123|cit123","first-page":"247","article-title":"Rituximab monotherapy is an effective induction therapy in proliferative lupus nephritis: a pilot study [abstract]","volume":"68","author":"Li","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/rheumatology\/kep124","article-title":"Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?","volume":"48","author":"Li","year":"2009","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0125|cit125","first-page":"391A","article-title":"Induction therapies for proliferative lupus nephritis: mycophenolate mofetil, tacrolimus and intravenous cyclophosphamide [abstract]","volume":"20","author":"Li","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub3-BIB0126|cit126","first-page":"S476","article-title":"Treatment of type iv lupus nephritis (LN) - comparison of 2 triple therapy regimens: cyclosporin a (CSA), prednisolone (PRED), azathioprine (AZA) vs. oral cyclophosphamide (POCP), prednisolone, azathioprine [abstract]","volume":"3","author":"Lui","year":"1997","journal-title":"Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub3-BIB0127|cit127","first-page":"573A","article-title":"Protocol for the Lupus Nephritis Assessment with rituximab (LUNAR) Study [abstract]","volume":"17","author":"Appel","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0128|cit128","first-page":"15","article-title":"Efficacy and safety of rituximab (RTX) in patients (Pts) with proliferative lupus nephritis (LN): results from randomized, double-blind phase III LUNAR study at week 52 [abstract]","volume":"19","author":"Furie","year":"2010","journal-title":"Lupus"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0129|cit129","first-page":"549","article-title":"Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study [abstract]","volume":"69","author":"Furie","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0130|cit130","unstructured":"Furie R Looney RJ Rovin B Latinis KM Appel G Sanchez-Guerrero J Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract 1149] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0131|cit131","first-page":"157","article-title":"Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial [abstract]","volume":"19","author":"Furie","year":"2010","journal-title":"Lupus"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0132|cit132","first-page":"550","article-title":"Effect of rituximab (RTX) on anti -double-stranded DNA antibody and c3 levels and relationship to response: results from the LUNAR trial [abstract]","volume":"69","author":"Furie","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0133|cit133","unstructured":"Furie R Rovin B Appel G Kamen DL Fervenza FC Spindler A Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial [abstract 271] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0134|cit134","first-page":"253","article-title":"Trial design and baseline characteristics of patients in the randomized double-blind, placebo-controlled phase III lupus nephritis assessment with rituximab study (LUNAR) [abstract]","volume":"68","author":"Furie","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0135|cit135","unstructured":"Rovin B Appel G Furie R Fervenza F Guerrero JS Lenz O Trial design and baseline characteristics of patients in the randomized double-blind, placebo-controlled phase III LUpus Nephritis Assessment with Rituximab study (LUNAR) [abstract M353] World Congress of Nephrology; 2009 May 22-26; Milan (Italy) 2009"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0136|cit136","first-page":"406A","article-title":"Effect of Rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: Results from the LUNAR Trial [abstract]","volume":"20","author":"Rovin","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0137|cit137","first-page":"77A","article-title":"Efficacy and safety of rituximab (RTX) in subjects with proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract]","volume":"20","author":"Rovin","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0139|cit139","first-page":"552","article-title":"Longterm renal outcome in lupus nephritis patients can be predicted by the kinetics of proteinuria drop in response to therapy: data from the MAINTAIN NEPHRITIS trial [abstract]","volume":"69","author":"Houssiau","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0140|cit140","unstructured":"Houssiau FA D'Cruz DP Sangle SR Remy P Vasconcelos C De Ramon Garrido E Azathioprine versus mycophenolate mofetil for maintenance immunosuppression of proliferative lupus nephritis: results of a randomized trial (MAINTAIN) [abstract 1150] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0141|cit141","first-page":"935","article-title":"Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial","volume":"22","author":"Mitwalli","year":"2011","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0142|cit142","unstructured":"Mok C Ying K Tong K Siu Y To C Yim C Mycophenolate mofetil versus tacrolimus for active lupus nephritis: an extended observation of a randomized controlled trial [abstract 1073] ACR\/ARHP Annual Scientific Meeting; 2008 Oct 24-29; San Francisco (CL) 2008"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD002922.pub3-BIB0149|cit143","first-page":"923","article-title":"Factors determining response in patients with acute lupus nephritis treated with glucocorticoids and mycophenolate mofetil (MMF) [abstract]","volume":"60","author":"Mok","year":"2009","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0143|cit144","first-page":"555","article-title":"Risk of renal flares and decline in renal function in patients with active lupus nephritis treated with mycophenolate mofetil (MMF) [abstract]","volume":"69","author":"Mok","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD002922.pub3-BIB0144|cit145","first-page":"477","article-title":"Risk of renal flares and decline in renal function in patients with active lupus nephritis treated with mycophenolate mofetil (MMF) [abstract]","volume":"60","author":"Mok","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0145|cit146","first-page":"155","article-title":"Factors determining response in patients with active lupus nephritis treated with glucocorticoids and mycophenolate mofetil (MMF) [abstract]","volume":"19","author":"Mok","year":"2010","journal-title":"Lupus"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0146|cit147","first-page":"16","article-title":"Tacrolimus (Tac) versus mycophenolate mofetil (MMF) for the treatment of membranous lupus nephritis: a randomized controlled trial [abstract]","volume":"19","author":"Mok","year":"2010","journal-title":"Lupus"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0147|cit148","first-page":"75","article-title":"Tacrolimus (tac) versus mycophenolate mofetil (mmf) for the treatment of membranous lupus nephritis: a randomized controlled trial [abstract]","volume":"69","author":"Mok","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0148|cit149","first-page":"246","article-title":"Mycophenolate mofetil versus tacrolimus for active lupus nephritis: an extended observation of a randomized controlled trial [abstract]","volume":"68","author":"Mok","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0150|cit150","unstructured":"Doria A Ponticelli C Mosca M Ferraccioli GF Moroni G Todesco S A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (USA) 2004"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","article-title":"A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years","volume":"1","author":"Moroni","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0152|cit152","first-page":"121A","article-title":"A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis [abstract]","volume":"15","author":"Moroni","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0153|cit153","unstructured":"Moroni G Doria A Mosca M Ferraccioli G Todesco S Schena P A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal) 2004 224"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0154|cit154","unstructured":"Mosca M Doria A Moroni G Ferrara R Todesco S Ponticelli C Induction therapy with oral cyclophosphamide in lupus nephritis [abstract THU0166] Annual European Congress of Rheumatology EULAR; 2002 June 12-15; Stockholm (Sweden) 2002"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub3-BIB0155|cit155","first-page":"349","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide in treatment of lupus nephritis [abstract]","volume":"67","author":"Mulic-Bacic","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0156|cit156","first-page":"626A","article-title":"Enteric-coated mycophenolate sodium (ED-MPS) for the treatment of lupus nephritis - MyLupus study [abstract]","volume":"21","author":"Jayne","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD002922.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0158|cit158","first-page":"559","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) in combination with two corticosteroid regimens for the treatment of lupus nephritis flare - results of the MYLUPUS study [abstract]","volume":"69","author":"Zeher","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0159|cit159","first-page":"250","article-title":"Enteric coated mycophenolate sodium (EC-MPS) treatment of lupus nephritis flare - interim results from a multicenter, randomized trial [abstract]","volume":"68","author":"Zeher","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5414\/CNP57108","article-title":"Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative lupus nephritis","volume":"57","author":"Nakamura","year":"2002","journal-title":"Clinical Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0162|cit161","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1440-1797.2005.00444.x","article-title":"Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis","volume":"10","author":"Ong","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0161|cit162","first-page":"A121","article-title":"Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis [abstract]","volume":"10","author":"Ong","year":"2005","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11255-007-9325-4","article-title":"A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: An Egyptian experience","volume":"41","author":"Sabry","year":"2009","journal-title":"International Urology & Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD002922.pub3-BIB0164|cit164","first-page":"vi28","article-title":"A comparative study of two intensified pulse cyclophosphamide remission-inducing regimen for diffuse proliferative lupus nephritis: an Egyptian experience [abstract]","volume":"22","author":"Sabry","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/096120339400300209","article-title":"A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis","volume":"3","author":"Sesso","year":"1994","journal-title":"Lupus"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub3-BIB0166|cit166","first-page":"286","article-title":"Pulse cyclophosphamide (CY) versus pulse methylprednisolone (MP) in severe lupus nephritis [abstract]","volume":"4","author":"Sesso","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-75-2-165","article-title":"Cyclophosphamide in lupus nephritis: a controlled trial","volume":"75","author":"Steinberg","year":"1971","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0168|cit168","unstructured":"Sundel RP Lisk L Mycophenolate mofetil compared with intravenous cyclophosphamide as induction treatment for pediatric lupus nephritis: a randomized trial [abstract 1247] American College of Rheumatology Annual Scientific Meeting, Oct 24-29, 2008, San Francisco (CL) 2008"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1098-1101(1998)13:4<163::AID-JCA4>3.0.CO;2-1","article-title":"Randomized controlled trial of pulse\/synchronization cyclophosphamide\/apheresis for proliferative lupus nephritis","volume":"13","author":"Wallace","year":"1998","journal-title":"Journal of Clinical Apheresis"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/ard.2002.003574","article-title":"EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis","volume":"63","author":"Yee","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD002922.pub3-BIB0171|cit171","first-page":"vi14","article-title":"Comparison between corticosteroid and mycophenolate mofetil and corticosteroid and cyclophosphamide in the treatment of lupus nephritis [abstract]","volume":"22","author":"Abedi","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub3-BIB0172|cit172","first-page":"18","article-title":"Efficacy of immunosorption in patients with systemic lupus erythematosus: double blind controlled trial","volume":"69","author":"Amosova","year":"1997","journal-title":"Terapevticheskii Arkhiv"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.reuma.2009.11.004","article-title":"Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study","volume":"6","author":"Andrade-Ortega","year":"2010","journal-title":"Reumatologia Clinica"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub3-BIB0174|cit174","first-page":"90A","article-title":"ACE inhibition reduces proteinuria, hematuria and renal expression of inflammatory mediators in human lupus nephritis [abstract]","volume":"12","author":"Antunes","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0175|cit175","unstructured":"Linnik MD Tansey MJ Joh T Dose dependent reduction in anti-dsDNA antibody levels observed with abetimus sodium through 52 weeks in the phase 3 ASPEN study (abetimus sodium in patients with a history of lupus nephritis) [abstract 1077] ACR\/ARHP Annual Scientific Meeting; 2008 Oct 24-29; San Francisco (CL) 2008"},{"issue":"Abstracts issue","key":"10.1002\/14651858.CD002922.pub3-BIB0176|cit176","first-page":"781A","article-title":"Interim analysis reveals dose dependent reduction in anti-dsDNA antibody levels with Abetimus sodium through 52 weeks in the phase 3 ASPEN study (Abetimus Sodium in Patients with a history of lupus Nephritis) [abstract]","volume":"19","author":"Tansey","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub3-BIB0177|cit177","first-page":"251","article-title":"Interim analysis reveals dose dependent reduction in anti-dsDNA antibody levels with Abetimus sodium through 52 weeks in the phase 3 ASPEN study (Abetimus Sodium in patients with a History of lupus Nephritis) [abstract]","volume":"68","author":"Tansey","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0179|cit179","first-page":"54A","article-title":"Long-term observations in a prospective clinical trial of prednisone, cyclosporine and cyclophosphamide for lupus membranous nephropathy (LMN) [abstract]","volume":"15","author":"Austin","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0180|cit180","first-page":"81A","article-title":"Lupus membranous nephropathy: randomized controlled trial of prednisolone, cyclosporine and cyclophosphamide [abstract]","volume":"11","author":"Austin","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub3-BIB0181|cit181","first-page":"1328","article-title":"Lupus membranous nephropathy: controlled trial of prednisolone, pulse cyclophosphamide, and cyclosporine A [abstract]","volume":"7","author":"Austin","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0182|cit182","first-page":"119","article-title":"Clinical trial of cyclophosphamide plus azathioprine and pulse cyclophosphamide in lupus nephritis [abstract]","volume":"19","author":"Balow","year":"1981","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0183|cit183","first-page":"158","article-title":"Influence of treatment on the evolution of renal pathology in lupus nephritis [abstract]","volume":"25","author":"Balow","year":"1984","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000330685","article-title":"Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis","volume":"34","author":"Ble","year":"2011","journal-title":"American Journal of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub3-BIB0185|cit185","first-page":"C111","article-title":"Reduced bone mineral density (BMD) in children with lupus nephritis (LN) treated with steroids [abstract]","volume":"16","author":"Bosque","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub3-BIB0186|cit186","first-page":"801A","article-title":"Treatment of lupus nephritis type IV and type V with leflunomide: a prospective middle-long period study [abstract]","volume":"17","author":"Cao","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0187|cit187","first-page":"309A","article-title":"Histopathological outcome in proliferative lupus nephritis patients who did not achieve good response after randomized to eurolupus or high-dose IV cyclophosphamide [abstract]","volume":"20","author":"Chanchairujira","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ki.1993.215","article-title":"Fish oil in lupus nephritis: clinical findings and methodological implications","volume":"44","author":"Clark","year":"1993","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0189|cit189","first-page":"309","article-title":"Fish oil in lupus nephritis a double-blind randomized crossover study [abstract]","volume":"3","author":"Clark","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/07315724.2001.10719026","article-title":"Flaxseed in lupus nephritis: a two-year nonplacebo-controlled crossover study","volume":"20","author":"Clark","year":"2001","journal-title":"Journal of the American College of Nutrition"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub3-BIB0191|cit191","first-page":"143A","article-title":"Flaxseed in lupus nephritis: a two year randomized cross-over study [abstract]","volume":"9","author":"Clark","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0192|cit192","first-page":"53A","article-title":"A multi-center controlled clinical trial of leflunomide treating proliferative lupus nephritis [abstract]","volume":"15","author":"Cui","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub3-BIB0193|cit193","first-page":"672","article-title":"Treatment of proliferative lupus nephritis with leflunomide and corticosteroid: a prospective multi-center controlled clinical trial","volume":"44","author":"Cui","year":"2005","journal-title":"Chung-Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub3-BIB0194|cit194","first-page":"450A","article-title":"Efficacy and safety of leflunomide in the treatment of proliferative lupus nephritis: preliminary results from a randomized, cyclophosphamide-controlled study [abstract]","volume":"14","author":"Cui","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jca.10020","article-title":"Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis","volume":"17","author":"Danieli","year":"2002","journal-title":"Journal of Clinical Apheresis"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1191\/096120399678847380","article-title":"Recombinant human Dnase I (rhDNase) in patients with lupus nephritis","volume":"8","author":"Davis","year":"1999","journal-title":"Lupus"},{"issue":"1-4","key":"10.1002\/14651858.CD002922.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.prostaglandins.2005.08.001","article-title":"Captopril effect on prostaglandin E2, thromboxane B2 and proteinuria in lupus nephritis patients","volume":"78","author":"Daza","year":"2005","journal-title":"Prostaglandins & Other Lipid Mediators"},{"issue":"24","key":"10.1002\/14651858.CD002922.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJM198412133112402","article-title":"Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis","volume":"311","author":"Felson","year":"1984","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.arcmed.2005.04.011","article-title":"Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofetil","volume":"37","author":"Flores-Suarez","year":"2006","journal-title":"Archives of Medical Research"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0200|cit200","first-page":"122A","article-title":"Open randomized trial comparing mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IV-CYC) as induction therapy for severe lupus nephritis (LN) [abstract]","volume":"15","author":"Flores-Suarez","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0201|cit201","unstructured":"Flores-Suarez LF Villa AR Preliminary results of an open randomised clinical trial comparing mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IV-CYC) as induction therapy for severe lupus nephritis [abstract THU0413] Annual European Congress of Rheumatology EULAR 2004; 2004 Jun 9-12, Berlin (Germany) 2004"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub3-BIB0202|cit202","first-page":"S476","article-title":"Intravenous cyclophosphamide pulse therapy for severe lupus nephritis: finding an optimal dose and duration [abstract]","volume":"3","author":"Frutos","year":"1997","journal-title":"Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub3-BIB0203|cit203","first-page":"50","article-title":"Triple therapy in children with lupus nephritis","volume":"61","author":"Futrakul","year":"1978","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0204|cit204","first-page":"1204","article-title":"Adjusted methylprednisolone dosing to serum albumin levels plus cyclophosphamide in patients with lupus nephritis. A pilot study [abstract]","volume":"38","author":"Gonzalez-Diaz","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00007611-198903000-00012","article-title":"Lupus nephritis: efficacy of monthly pulse therapy with intravenous methylprednisolone","volume":"82","author":"Harisdangkul","year":"1989","journal-title":"Southern Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0206|cit206","first-page":"201","article-title":"Clinical course of severe lupus nephritis during the controlled clinical trial of plasmapheresis [abstract]","volume":"31","author":"Hebert","year":"1987","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0207|cit207","first-page":"616","article-title":"Double blind trial of pulse methylprednisolone versus conventional oral prednisolone in lupus nephritis","volume":"34","author":"Honma","year":"1994","journal-title":"Ryumachi"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0208|cit208","first-page":"705","article-title":"Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis","volume":"115","author":"Hu","year":"2002","journal-title":"Chinese Medical Journal"},{"issue":"Sept","key":"10.1002\/14651858.CD002922.pub3-BIB0209|cit209","first-page":"89A","article-title":"Comparison of mycophenolate mofetil (MMF) vs cyclophosphamide (CTX) pulse therapy in the induction treatment of severe diffuse proliferative lupus nephritis (DPLN) in Chinese population [abstract]","volume":"11","author":"Li","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0210|cit210","unstructured":"Jigui C Tai L Clinical study in 12 patients lupus nephritis with low dose and long time sandimmun neoral [abstract] 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong 1995 115"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0212|cit211","unstructured":"Jigui C Li T Clinical study on 18 patients lupus nephritis (ln) with low dose and long time for mycophenolate mofetil (Cellcept) [abstract] 8th Asian Pacific Congress of Nephrology; 2000 Mar 26-30; Taipei 2000 264"},{"issue":"Sept","key":"10.1002\/14651858.CD002922.pub3-BIB0211|cit212","first-page":"213A","article-title":"Clinical study on 18 patients lupus nephritis (ln) with low dose and long time for mycophenolate mofetil (Cellcept) [abstract]","volume":"12","author":"Jigui","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1592\/phco.21.6.528.34549","article-title":"Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis","volume":"21","author":"Kuo","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0214|cit214","first-page":"556A","article-title":"Controlled trial of tacrolimus (FK506) vs intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis [abstract]","volume":"16","author":"Li","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD002922.pub3-BIB0215|cit215","first-page":"iv74","article-title":"Plasma exchange and immunoadsorption in the treatment of severe lupus nephritis [abstract]","volume":"21","author":"Li","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0216|cit216","first-page":"S272","article-title":"SLE trial shows fewer renal flares in LJP 394-treated patients with high affinity antibodies to LJP 394: 90-05 trial results [abstract]","volume":"43","author":"Alarcon-Segovia","year":"2000","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/art.10763","article-title":"LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study","volume":"48","author":"Alarcon-Segovia","year":"2003","journal-title":"Arthritis & Rheumatism"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0218|cit218","first-page":"113A","article-title":"Integrated safety results from studies of LJP394 in SLE patients [abstract]","volume":"15","author":"Hura","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0220|cit219","unstructured":"Linnik MD Hu JZ Heilbrunn KR Strand V Hurley FL Joh T Anti-dsDNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus: results from 2 randomized controlled trials with LJP394 [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (USA) 2004"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0219|cit220","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.20980","article-title":"Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus","volume":"52","author":"Linnik","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub3-BIB0221|cit221","first-page":"450A","article-title":"Reductions in anti-dsDNA antibodies and reduced risk of SLE renal flare and major SLE flare. [abstract]","volume":"14","author":"Linnik","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub3-BIB0223|cit222","first-page":"449A","article-title":"Renal flare in SLE patients with impaired renal function in a RCT of LJP 394 [abstract]","volume":"14","author":"Tumlin","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0222|cit223","unstructured":"Tumlin JA Cardiel MH Furie RA Wallace DJ Hura C Foster T Reductions in 24 hour urine protein levels associated with treatment of lupus patients withLJP 394 in two randomized, placebo controlled, double-blind clinical trials [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (USA) 2004"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0224|cit224","first-page":"121A","article-title":"Reductions in 24-hour urine protein levels associated with treatment of SLE patients with LJP394 in two randomized, placebo-controlled clinical trials [abstract]","volume":"15","author":"Tumlin","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub3-BIB0225|cit225","first-page":"253A","article-title":"The B-cell tolerogen LJP-394 reduces renal flares in patients with lupus nephritis: a prospective, double-blinded, placebo controlled trial [abstract]","volume":"12","author":"Tumlin","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0226|cit226","unstructured":"Cardiel MH LJP 394-90-09 Study Investigators Randomized, placebo controlled, double blind phase III trial for the evaluation of LJP 394 (Abetimus sodium) in the treatment of patients with SLE who are at risk of renal flare [abstract OP0053] Annual European Congress of Rheumatology EULAR; 2003 June 18-21; Lisbon (Portugal) 2003"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1002\/art.23673","article-title":"Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial","volume":"58","author":"Cardiel","year":"2008","journal-title":"Arthritis & Rheumatism"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0228|cit228","first-page":"113A","article-title":"Integrated safety results from studies of LJP394 in SLE patients [abstract]","volume":"15","author":"Hura","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0230|cit229","unstructured":"Linnik MD Hu JZ Heilbrunn KR Strand V Hurley FL Joh T Anti-dsDNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus: results from 2 randomized controlled trials with LJP394 [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (USA) 2004"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0229|cit230","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.20980","article-title":"Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus","volume":"52","author":"Linnik","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub3-BIB0231|cit231","first-page":"450A","article-title":"Reductions in anti-dsDNA antibodies and reduced risk of SLE renal flare and major SLE flare [abstract]","volume":"14","author":"Linnik","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub3-BIB0233|cit232","first-page":"449A","article-title":"Renal flare in SLE patients with impaired renal function in a RCT of LJP 394 [abstract]","volume":"14","author":"Tumlin","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0232|cit233","unstructured":"Tumlin JA Cardiel MH Furie RA Wallace DJ Hura C Foster T Reductions in 24 hour urine protein levels associated with treatment of lupus patients with LJP 394 in two randomized, placebo controlled, double-blind clinical trials [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (USA) 2004"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub3-BIB0234|cit234","first-page":"449A","article-title":"Efficacy results from a RCT of LJP 394 in SLE patients with history of renal disease [abstract]","volume":"14","author":"Tumlin","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0235|cit235","first-page":"791A","article-title":"The effect of LJP394 and concomitant immunosuppressive agents on levels of anti-dsDNA antibodies in SLE patients [abstract]","volume":"15","author":"Tumlin","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub3-BIB0236|cit236","first-page":"121A","article-title":"Reductions in 24-hour urine protein levels associated with treatment of SLE patients with LJP394 in two randomized, placebo-controlled clinical trials [abstract]","volume":"15","author":"Tumlin","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub3-BIB0237|cit237","first-page":"449A","article-title":"Safety results from a RCT of LJP 394 in SLE patients with a history of renal disease [abstract]","volume":"14","author":"Wallace","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.transci.2010.10.003","article-title":"Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis","volume":"43","author":"Loo","year":"2010","journal-title":"Transfusion & Apheresis Science"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0239|cit239","first-page":"169","article-title":"Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis","volume":"22","author":"Lu","year":"2002","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0241|cit241","unstructured":"Monova D Monov S Rashkov R Scheitanov J Belovezhdov N High-risk features of lupus nephritis: clinical and histological factors in 86 patients [abstract] 37th Congress.European Renal Association.European Dialysis and Transplantation Association.European Kidney Research Organisation; 2000 Sept 17-20; Nice (France) 2000 112"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/art.22581","article-title":"Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus","volume":"56","author":"Nakayamada","year":"2007","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0243|cit243","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Immunosuppressive drug therapy in membranous lupus nephropathy clinicaltrials.gov\/ct2\/show\/NCT00001212"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0244|cit244","first-page":"281","article-title":"Low does aspirin in patients with lupus nephritis [abstract]","volume":"33","author":"Pierucci","year":"1988","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0245|cit245","first-page":"283","article-title":"Acute effects of a thromboxane receptor antagonist on renal function in patients with lupus nephritis [abstract]","volume":"31","author":"Pierucci","year":"1987","journal-title":"Kidney International"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM198902163200703","article-title":"Improvement of renal function with selective thromboxane antagonism in lupus nephritis","volume":"320","author":"Pierucci","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0247|cit247","first-page":"269","article-title":"Clinical observations on treatment of lupus nephritis with kidney-nourishing and toxin-removing method - A report of 60 cases","volume":"26","author":"Qi","year":"2006","journal-title":"Journal of Traditional Chinese Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0248|cit248","first-page":"360A","article-title":"Short term cyclophosphamide (cp) bolus therapy for lupus nephritis [abstract]","volume":"5","author":"Schaumann","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0249|cit249","doi-asserted-by":"crossref","unstructured":"Schaumann D Hein R Schmidt RE Brunkhorst R Neumann KH Deicher H Intravenous cyclophosphamide (cp) pulse therapy for lupus nephritis - duration of induction therapy [abstract] International Symposium on Pathogenesis, Pathophysiology & Therapy of Glomerulonephritis; 1992 Dec 3-5; Bruges (Belgium) 1992 60","DOI":"10.1159\/000186790"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub3-BIB0250|cit250","first-page":"2602","article-title":"Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis","volume":"26","author":"Spertini","year":"1999","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000421688","article-title":"Approach to lupus nephritis based upon randomized trials","volume":"99","author":"Steinberg","year":"1992","journal-title":"Contributions to Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3736\/jcim20070309","article-title":"Effect of intravenous drip infusion of cyclophosphamide with high-dose Astragalus injection in treating lupus nephritis","volume":"5","author":"Su","year":"2007","journal-title":"Zhong Xi Yi Jie He Xue Bao [Journal of Chinese Integrative Medicine]"},{"issue":"14","key":"10.1002\/14651858.CD002922.pub3-BIB0253|cit253","first-page":"1029","article-title":"Plasmapheresis for lupus nephritis","volume":"327","author":"Wallace","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0254|cit254","unstructured":"Wallace DJ Lisse J Stohl W McKay J Boling E Merrill JT Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks [abstract 2012] ACR\/ARHP Annual Scientific Meeting; 2006 Nov 11-15; Washington (DC) 2006"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/0961203307081340","article-title":"Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide","volume":"16","author":"Wang","year":"2007","journal-title":"Lupus"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0256|cit256","first-page":"57","article-title":"Cyclophosphamide pulse therapy of systemic lupus erythematosus with renal involvement","volume":"19","author":"Hein","year":"1991","journal-title":"Immunitat und Infektion"},{"issue":"27-28","key":"10.1002\/14651858.CD002922.pub3-BIB0257|cit257","first-page":"1005","article-title":"Cyclophosphamide bolus therapy in lupus nephritis","volume":"118","author":"Witte","year":"1993","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub3-BIB0258|cit258","first-page":"24","article-title":"Cyclophosphamide bolus therapy in lupus nephritis - status of the clinical study","volume":"21","author":"Witte","year":"1993","journal-title":"Immunitat und Infektion"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub3-BIB0259|cit259","first-page":"718","article-title":"Clinical observation on nephrotic syndrome of lupus nephritis treated with integrated traditional Chinese and Western Medicine","volume":"18","author":"Wu","year":"1998","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub3-BIB0260|cit260","first-page":"S475","article-title":"Observation of therapy with integrated TCM-WM on 74 lupus nephritis patients [abstract]","volume":"3","author":"Ye","year":"1997","journal-title":"Nephrology"},{"issue":"Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0261|cit261","first-page":"S99","article-title":"MMF vs CTX in the treatment of severe SLE patients [abstract]","volume":"10","author":"Ye","year":"2001","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0262|cit262","unstructured":"Yin P Yang Y Clinical evaluation on Cyclosporin A in treatment of lupus nephritis [abstract] 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong 1995 115"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub3-BIB0263|cit263","first-page":"684","article-title":"A clinical study on low dose cyclosporine A in the treatment of lupus nephritis","volume":"33","author":"Yin","year":"1994","journal-title":"Zhonghua Nei Za Zhi"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub3-BIB0264|cit264","first-page":"1719","article-title":"Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis","volume":"23","author":"Yoshida","year":"1996","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-4899-1810-9_23","article-title":"Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis","volume":"433","author":"Yoshida","year":"1997","journal-title":"Advances in Experimental Medicine & Biology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD002922.pub3-BIB0266|cit266","first-page":"356","article-title":"Cyclophosphamide (CTX) pulse therapy in lupus nephritis (LN): short term is better [abstract]","volume":"18","author":"Zhang","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0267|cit267","unstructured":"Zhang JH Yang H Cyclophosphamide (ctx) pulse therapy in lupus nephritis (ln): short term is better [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain) 1995 290"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub3-BIB0268|cit268","first-page":"983","article-title":"Intervention of liuwei dihuang pill on lupus nephropathy treated with cyclophosphamide and glucocorticoids","volume":"25","author":"Zheng","year":"2005","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0269|cit269","unstructured":"Wofsy D Diamond B A randomized, double-blind, controlled, phase ii multicenter trial of CTLA4IG (abatacept) plus cyclophosphamide vs cyclophosphamide alone in the treatment of lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT00774852"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub3-BIB0270|cit270","first-page":"156","article-title":"Study design and baseline patient characteristics of BELONG, the randomized double-blind, placebo-controlled phase III trial of ocrelizumab, a humanized anti-CD20 antibody, in lupus nephritis [abstract]","volume":"19","author":"Mysler","year":"2010","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0271|cit271","unstructured":"Avihingsanon Y The clinical efficacy and economic evaluation of ec-mps (myfortic) in the treatment of relapse or resistant proliferative lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT01015456"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0272|cit272","unstructured":"NCT00425438 A randomized, open-label study to compare the effect of cellcept plus corticosteroids, and cyclophosphamide plus corticosteroids followed by azathioprine, on remission rate in patients with lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT00425438"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0273|cit273","unstructured":"Liu Z An multi-site, open, prospective study to assess the efficacy and safety of multi-target therapy in the treatment of class iii, iv, v+iii and v+iv lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT00876616"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0274|cit274","unstructured":"Hu W To compare the efficacy and safety of tripterygium (TW) vs AZA in the maintenance therapy for lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT00881309"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0275|cit275","unstructured":"NCT01172002 A randomized multicenter trial comparing leflunomide and azathioprine as remission-maintaining treatment for proliferative lupus glomerulonephritis www.clinicaltrials.gov\/ct2\/show\/NCT01172002"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0276|cit276","unstructured":"NCT01273389 A multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate safety and efficacy of treatment with CNTO 136 administered intravenously in subjects with active lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT01273389"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0277|cit277","unstructured":"Gema FJ Phase III, open, randomized, parallel-group clinical trial, to evaluate the efficacy and safety of treatment with prednisone, cyclosporine, mycophenolic acid versus prednisone and mycophenolic acid in lupus nephritis type III-IV-V www.clinicaltrials.gov\/ct2\/show\/NCT01299922"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0278|cit278","unstructured":"NCT01342016 A randomized, double-blind double dummy, parallel control and multi-center clinical trial to compare the efficacy and safety of tacrolimus capsules in treatment of lupus nephritis with leflunomide tablets www.clinicaltrials.gov\/ct2\/show\/NCT01342016"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0279|cit279","unstructured":"Bijl M Comparison of short course cyclophosphamide followed by mycophenolate mofetil versus long course cyclophosphamide in the treatment of proliferative lupus nephritis www.controlled-trials.com\/ISRCTN34634478 2006"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/rheumatology\/kel039","article-title":"An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period","volume":"45","author":"Adler","year":"2006","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0281|cit281","unstructured":"Grace B Excell L Dent H Mc Donald S New patients commencing treatment in 2009. The 33rd Annual Report 2010 Report - Data to 2009 http:\/\/www.anzdata.org.au\/anzdata\/AnzdataReport\/33rdReport\/Ch02.pdf"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub3-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1681\/ASN.V102413","article-title":"Lupus nephritis","volume":"10","author":"Cameron","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/sj.ki.5000243","article-title":"Outcomes in African Americans and Hispanics with lupus nephritis","volume":"69","author":"Contreras","year":"2006","journal-title":"Kidney International"},{"issue":"7305","key":"10.1002\/14651858.CD002922.pub3-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","article-title":"Systematic reviews in health care: Systematic review of evaluations of diagnostic and screening tests","volume":"323","author":"Deeks","year":"2001","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/ki.1997.162","article-title":"Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network","volume":"51","author":"Dooley","year":"1997","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0287|cit287","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0288|cit288","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1523-1755.2000.00832.x","article-title":"Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide","volume":"57","author":"Ioannidis","year":"2000","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MD.0b013e3181e93d00","article-title":"Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis","volume":"89","author":"Kamanamool","year":"2010","journal-title":"Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","article-title":"Severe lupus nephritis: racial differences in presentation and outcome","volume":"18","author":"Korbet","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/0961203309357763","article-title":"Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis","volume":"19","author":"Lee","year":"2010","journal-title":"Lupus"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/kep120","article-title":"Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression","volume":"48","author":"Mak","year":"2009","journal-title":"Rheumatology"},{"issue":"9193","key":"10.1002\/14651858.CD002922.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/art.10138","article-title":"Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine","volume":"46","author":"Mok","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"R182","DOI":"10.1186\/ar2093","article-title":"Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis","volume":"8","author":"Moore","year":"2006","journal-title":"Arthitis Research & Therapy"},{"key":"10.1002\/14651858.CD002922.pub3-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1191\/096120398678920776","article-title":"Flares in lupus nephritis: impact on renal survival and management","volume":"7","author":"Ponticelli","year":"1998","journal-title":"Lupus"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ki.2009.412","article-title":"Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis","volume":"77","author":"Radhakrishnan","year":"2010","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3899\/jrheum.100130","article-title":"Mycophenolate Mofetil for induction treatment of lupus nephritis: a systematic review and meta-analysis","volume":"38","author":"Touma","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub3-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2215\/CJN.01200307","article-title":"Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis","volume":"2","author":"Walsh","year":"2007","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/ndt\/gfm066","article-title":"Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials","volume":"22","author":"Zhu","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub3-BIB0303|cit303","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002922","article-title":"Treatment for lupus nephritis","author":"Flanc","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub3-BIB0304|cit304","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002922.pub2","article-title":"Treatment for lupus nephritis","author":"Flanc","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub3-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2003.10.012","article-title":"Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials","volume":"43","author":"Flanc","year":"2004","journal-title":"American Journal of Kidney Diseases"}],"updated-by":[{"DOI":"10.1002\/14651858.cd002922.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002922.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T20:18:23Z","timestamp":1714681103000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002922.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":305,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002922.pub3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969408.793470553","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,12]]}}}